Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved..
Tumor-derived lactic acid inhibits T and natural killer (NK) cell function and, thereby, tumor immunosurveillance. Here, we report that melanoma patients with high expression of glycolysis-related genes show a worse progression free survival upon anti-PD1 treatment. The non-steroidal anti-inflammatory drug (NSAID) diclofenac lowers lactate secretion of tumor cells and improves anti-PD1-induced T cell killing in vitro. Surprisingly, diclofenac, but not other NSAIDs, turns out to be a potent inhibitor of the lactate transporters monocarboxylate transporter 1 and 4 and diminishes lactate efflux. Notably, T cell activation, viability, and effector functions are preserved under diclofenac treatment and in a low glucose environment in vitro. Diclofenac, but not aspirin, delays tumor growth and improves the efficacy of checkpoint therapy in vivo. Moreover, genetic suppression of glycolysis in tumor cells strongly improves checkpoint therapy. These findings support the rationale for targeting glycolysis in patients with high glycolytic tumors together with checkpoint inhibitors in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Cell reports - 29(2019), 1 vom: 01. Okt., Seite 135-150.e9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Renner, Kathrin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.09.2020 Date Revised 17.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2019.08.068 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301852618 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301852618 | ||
| 003 | DE-627 | ||
| 005 | 20231226200629.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2019.08.068 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1006.xml |
| 035 | |a (DE-627)NLM301852618 | ||
| 035 | |a (NLM)31577944 | ||
| 035 | |a (PII)S2211-1247(19)31123-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Renner, Kathrin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.09.2020 | ||
| 500 | |a Date Revised 17.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Tumor-derived lactic acid inhibits T and natural killer (NK) cell function and, thereby, tumor immunosurveillance. Here, we report that melanoma patients with high expression of glycolysis-related genes show a worse progression free survival upon anti-PD1 treatment. The non-steroidal anti-inflammatory drug (NSAID) diclofenac lowers lactate secretion of tumor cells and improves anti-PD1-induced T cell killing in vitro. Surprisingly, diclofenac, but not other NSAIDs, turns out to be a potent inhibitor of the lactate transporters monocarboxylate transporter 1 and 4 and diminishes lactate efflux. Notably, T cell activation, viability, and effector functions are preserved under diclofenac treatment and in a low glucose environment in vitro. Diclofenac, but not aspirin, delays tumor growth and improves the efficacy of checkpoint therapy in vivo. Moreover, genetic suppression of glycolysis in tumor cells strongly improves checkpoint therapy. These findings support the rationale for targeting glycolysis in patients with high glycolytic tumors together with checkpoint inhibitors in clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a NK cells | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a acidification | |
| 650 | 4 | |a checkpoint | |
| 650 | 4 | |a diclofenac | |
| 650 | 4 | |a glycolysis | |
| 650 | 4 | |a interferon gamma | |
| 650 | 4 | |a lactate | |
| 650 | 4 | |a monocarboxylate transporters | |
| 650 | 4 | |a tumor | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Bruss, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Schnell, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Koehl, Gudrun |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Holger M |e verfasserin |4 aut | |
| 700 | 1 | |a Fante, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Menevse, Ayse-Nur |e verfasserin |4 aut | |
| 700 | 1 | |a Kauer, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Blazquez, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Hacker, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Decking, Sonja-Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Bohn, Toszka |e verfasserin |4 aut | |
| 700 | 1 | |a Faerber, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Evert, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Aigle, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Amslinger, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Landa, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Krijgsman, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Rozeman, Elisa A |e verfasserin |4 aut | |
| 700 | 1 | |a Brummer, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Siska, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Katrin |e verfasserin |4 aut | |
| 700 | 1 | |a Pektor, Stefanie |e verfasserin |4 aut | |
| 700 | 1 | |a Miederer, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Peter, Katrin |e verfasserin |4 aut | |
| 700 | 1 | |a Gottfried, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Herr, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Marchiq, Ibtisam |e verfasserin |4 aut | |
| 700 | 1 | |a Pouyssegur, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Roush, William R |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, SuFey |e verfasserin |4 aut | |
| 700 | 1 | |a Warren, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Pukrop, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Beckhove, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Sven A |e verfasserin |4 aut | |
| 700 | 1 | |a Bopp, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Blank, Christian U |e verfasserin |4 aut | |
| 700 | 1 | |a Cleveland, John L |e verfasserin |4 aut | |
| 700 | 1 | |a Oefner, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Dettmer, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Selby, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Kreutz, Marina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 29(2019), 1 vom: 01. Okt., Seite 135-150.e9 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2019 |g number:1 |g day:01 |g month:10 |g pages:135-150.e9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2019.08.068 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2019 |e 1 |b 01 |c 10 |h 135-150.e9 | ||